Financial insights of VTVT

MyFinsight

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenue	36,839,000	0	0	0
Research and development	8,978,000	3,908,000	7,020,000	4,103,000
General and administrative	4,598,000	3,977,000	3,679,000	3,618,000
Total operating expenses	13,576,000	7,885,000	10,699,000	7,721,000
Operating income (loss)	23,263,000	-7,885,000	-10,699,000	-7,721,000
Other income (expense), net-Nonrelated Party	9,000	-70,000	-34,000	12,000
Other income (expense), net-Related Party	24,000	-47,000	-6,000	54,000
Interest income	838,000	865,000	399,000	275,000
Interest expense	NaN	1,000	5,000	NaN
Income (loss) before income taxes and noncontrolling interest	24,134,000	-7,138,000	-10,345,000	-7,380,000
U.s. statutory tax benefit	NaN	-1,631,750*	NaN	NaN
Change in valuation allowance	NaN	1,731,250*	NaN	NaN
Tax credits	NaN	80,750*	NaN	NaN
Other	NaN	18,750*	NaN	NaN
Income tax provision	0	0	0	0
Net income (loss) before noncontrolling interest	24,134,000	-7,138,000	-10,345,000	-7,380,000
Less net loss attributable to noncontrolling interest	0	0	-1,647,000	-1,334,000
Net income (loss) attributable to vtv therapeutics inc	24,134,000	-7,138,000	-8,698,000	-6,046,000

Basic EPS	1.94	-0.671	-1.08	NaN
Diluted EPS	1.65	-0.671	-1.08	NaN
Basic Average Shares	12,409,278	10,632,112	8,055,940	NaN
Diluted Average Shares	14,634,420	10,632,112	8,055,940	NaN

Unit: Dollar. Numbers labeled with * are estimated quarterly values.